CALA · Calithera Biosciences Inc

-

Please sign in to comment on CALA

1 Comment

Admin

4 years ago

Calithera Biosciences, Inc is currently in a long term downtrend where the price is trading 39.1% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Calithera Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 3.9% to $-23M since the same quarter in the previous year.

Finally, its free cash flow fell by 25.2% to $-23M since the same quarter in the previous year.

Based on the above factors, Calithera Biosciences, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
CurrencyCode	USD
ISIN	US13089P5070
Exchange	PINK

Market Cap	24K
PE Ratio	None
Target Price	5
Beta	-1.16
Dividend Yield	None

ABOUT

Calithera Biosciences Inc

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

CALA · Calithera Biosciences Inc

-

Calithera Biosciences Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Calithera Biosciences Inc using a moving average strategy